MAP2K7 and colorectal carcinoma: In a preclinical study, the oral drug D-1553 (garsorasib) designed by InventisBio has been assessed in CRC cell lines and patient-derived xenografts in monotherapy form or in combination with an MEK inhibitor, SHP2 inhibitor, or chemotherapeutic compounds.